StockDuty ← Dashboard Nov 09, 2026 12:13 PM ET
SignalCorporate

TG Therapeutics GAAP EPS of $0.35 misses by $0.01, revenue of $259.9M beats by $14.45M

Revenue beat of $14.45M offsets EPS miss of $0.01.

What happened: TG Therapeutics reported Q3 GAAP EPS of $0.35, missing by $0.01, while revenue of $259.9M beat by $14.45M. The company raised full-year 2026 revenue guidance. Key numbers: Q3 GAAP EPS $0.35 (missed by $0.01); revenue $259.9M, up 60.7% Y/Y (beat by $14.45M); BRIUMVI U.S. net product revenue about $233M; FY2026 global revenue guidance raised to about $1 billion from about $950M vs $960.26M consensus; BRIUMVI U.S. Why it matters: The revenue beat and higher guidance contrast with the slight EPS miss, and shares rose 7% after hours. Coverage: 3 outlets in 24h
TG Therapeutics reported Q3 GAAP EPS of $0.35, missing by $0.01, while revenue of $259.9M beat by $14.45M. The company raised full-year 2026 revenue guidance.
The revenue beat and higher guidance contrast with the slight EPS miss, and shares rose 7% after hours.
Sources